Literature DB >> 22322237

Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.

Virendra Singh1, Souvik Ghosh, Baljinder Singh, Pradeep Kumar, Navneet Sharma, Ashish Bhalla, A K Sharma, N S Choudhary, Yogesh Chawla, C K Nain.   

Abstract

BACKGROUND & AIMS: Various vasoconstrictors are useful in the management of hepatorenal syndrome (HRS). Terlipressin is the drug of choice; however, it is expensive. In this study, we evaluated safety and efficacy of terlipressin and noradrenaline in the treatment of HRS.
METHODS: Forty-six patients with HRS type 1 were managed with terlipressin (group A, N=23) or noradrenaline (Group B, N=23) with albumin in a randomized controlled trial at a tertiary center.
RESULTS: HRS reversal could be achieved in 9 (39.1%) patients in group A and 10 (43.4%) patients in group B (p=0.764). Univariate analysis showed baseline Child Turcotte Pugh score (CTP), model of end stage liver disease (MELD), urine output on day 1(D1), albumin, and mean arterial pressure (MAP) were associated with response. However, on multivariate analysis only CTP score was associated with response. Fourteen patients in group A and 12 in group B died at day 15 (p>0.05). Noradrenaline was less expensive than terlipressin (p<0.05). No major adverse effects were seen.
CONCLUSIONS: The results of this randomized study suggest that noradrenaline is as safe and effective as terlipressin, but less expensive in the treatment of HRS and baseline CTP score is predictive of response.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322237     DOI: 10.1016/j.jhep.2012.01.012

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  56 in total

1.  [6 years of the International Union of Societies of Immunology. Presidential report (Brighton 1974)].

Authors:  B Cinader
Journal:  Medicina (B Aires)       Date:  1975 Jul-Aug       Impact factor: 0.653

Review 2.  Hepatology in India and INASL: A Ringside View.

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

Review 3.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

4.  Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study.

Authors:  Geetha Maddukuri; Cindy X Cai; Satish Munigala; Farnaz Mohammadi; Zhiwei Zhang
Journal:  Dig Dis Sci       Date:  2013-10-22       Impact factor: 3.199

5.  Randomized Controlled Trial Comparing the Efficacy of Terlipressin and Albumin with a Combination of Concurrent Dopamine, Furosemide, and Albumin in Hepatorenal Syndrome.

Authors:  Siddharth Srivastava; Sreenivas Vishnubhatla; Shyam Prakash; Hanish Sharma; Bhaskar Thakur; Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2015-09-01

Review 6.  Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.

Authors:  Gaetano Bertino; Graziella Privitera; Francesco Purrello; Shirin Demma; Emanuele Crisafulli; Luisa Spadaro; Nikolaos Koukias; Emmanuel A Tsochatzis
Journal:  Intern Emerg Med       Date:  2016-06-07       Impact factor: 3.397

Review 7.  [Hepatorenal syndrome in decompensated cirrhosis : A special form of acute renal failure].

Authors:  K Lenz; R Buder; G Lohr; P Piringer; M Voglmayr
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-05-30       Impact factor: 0.840

8.  Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.

Authors:  Juan Carlos Q Velez; Manish Kadian; Margarita Taburyanskaya; Nicole M Bohm; Tracie A Delay; Nithin Karakala; Don C Rockey; Paul J Nietert; Andrew J Goodwin; Timothy P Whelan
Journal:  Nephron       Date:  2015-10-21       Impact factor: 2.847

Review 9.  Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Authors:  Hiroshi Fukui; Hidetsugu Saito; Yoshiyuki Ueno; Hirofumi Uto; Katsutoshi Obara; Isao Sakaida; Akitaka Shibuya; Masataka Seike; Sumiko Nagoshi; Makoto Segawa; Hirohito Tsubouchi; Hisataka Moriwaki; Akinobu Kato; Etsuko Hashimoto; Kojiro Michitaka; Toshikazu Murawaki; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-31       Impact factor: 7.527

10.  Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus.

Authors:  Juan P Arab; Juan C Claro; Juan P Arancibia; Jorge Contreras; Fernando Gómez; Cristian Muñoz; Leyla Nazal; Eric Roessler; Rodrigo Wolff; Marco Arrese; Carlos Benítez
Journal:  World J Hepatol       Date:  2016-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.